Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rosetta Genomics Expands Management Team

Published: Tuesday, August 26, 2014
Last Updated: Tuesday, August 26, 2014
Bookmark and Share
Brings extensive track record in leading commercial teams and driving revenues in microRNA, oncology and thyroid diagnostics.

Rosetta Genomics Ltd. has announced the appointment of Douglas Sites to the newly-created position of Executive Vice President of Sales and Marketing. Mr. Sites will report to Kenneth A. Berlin, Rosetta's President and Chief Executive Officer.

Mr. Sites joins Rosetta Genomics with more than 25 years of experience in the sales and marketing of medical products, predominantly in diagnostics and laboratory services. Most recently he was Vice President of Sales and Marketing at Asuragen, a high-complexity CLIA laboratory with a focus on microRNA-based diagnostics as well as indeterminate thyroid diagnostics.

"We are delighted to welcome Doug to Rosetta's leadership team. His relevant skillset and depth of experience make him ideally suited to lead our commercial team as we expand Rosetta's commercial capabilities to drive sales of our Cancer of Origin test and prepare for the launch of our microRNA-based thyroid cancer assay, currently in development," stated Mr. Berlin. "As we expand our oncology diagnostic offerings, Doug's insight into both the thyroid and oncology markets, along with his experience building teams, brands and revenues will be invaluable. We look forward to his stewardship of our commercial efforts and are confident he will be an important asset to our team."

"I am excited to be joining the Rosetta Genomics team at this important point in our commercial evolution. With a leadership position in microRNA-based technologies, four marketed cancer diagnostic assays, a promising and diversified pipeline of late-stage product candidates and a talented leadership team, Rosetta holds significant promise to develop into a premier molecular diagnostics company. I look forward to being an instrumental part of Rosetta's growth as we advance our commercial strategy to bring meaningful diagnostics to market to the benefit of the physicians, and ultimately, the patients worldwide," noted Mr. Sites.

Prior to Asuragen, Mr. Sites was Director of Sales-Hematology and Oncology at PLUS Diagnostics, a national anatomical pathology reference laboratory that focuses on hematology oncology physicians. Before that he was with Phenopath Laboratories as Director of Sales and Marketing for this national anatomical pathology reference laboratory that focuses on hospitals, pharmaceutical companies and hematology/oncology markets.

Earlier he was an Anatomic Pathology Specialist at US Labs, Inc., where he designed and developed a selling tool used by the US Lab sales team when competing with in-house immunohistochemistry testing. In addition, Mr. Sites held a number of sales and marketing management positions of increasing responsibility at Ventana Medical Systems, Abbott Diagnostics and McNeil Consumer Products Company, among others. Mr. Sites earned his BA in Business Management and Marketing at The Ohio State University.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rosetta Genomics Receives Patent Allowances for MicroRNA-Based Cancer Treatment
Rosetta Genomics receives U.S. patent allowance for microRNA-based ovarian cancer treatment, plus receives two notices of allowance in Israel.
Tuesday, July 12, 2016
Rosetta Genomics Receives Approval from New York State
Company has received approval from the NY State for HEME FISH-based tests for detection of amplifications or rearrangements of DNA in a number of hematologic cancers.
Saturday, June 25, 2016
Rosetta Receives Approval for RosettaGX Reveal™
Company has announced conditional approval status for RosettaGX Reveal™, its novel microRNA classifier for the diagnosis of indeterminate thyroid fine needle aspirate.
Friday, March 04, 2016
Rosetta Genomics to Acquire PersonalizeDx
Rosetta will gain proprietary tests in prostate, bladder and lung cancer.
Monday, April 13, 2015
Rosetta Genomics Launch Admera’s Sequencing-Based Oncology Tests
The tests will help to predict patient’ responses to drugs based on their personal genetic makeup.
Monday, January 12, 2015
Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance
Leverages strengths of both organizations to develop diagnostic assays for important, unmet needs in cancer.
Friday, September 05, 2014
Rosetta Genomics Announces Agreement with Global Pharmaceutical Company
Leverages Rosetta's microRNA biomarker platform and expertise and global pharmaceutical Company's expertise in Alzheimer's biology and drug development to develop a diagnostic for the early detection of Alzheimer's disease.
Tuesday, August 05, 2014
Rosetta Genomics Announces NGS Research Collaboration with Weizmann Institute
Developing novel methods for next-generation sequencing of small RNAs.
Friday, August 01, 2014
Rosetta Genomics Receives Final New York State Approval
Proprietary microRNA diagnostic for identification of four major subtypes of kidney cancer now available in all 50 U.S. states.
Saturday, July 26, 2014
Rosetta Receives Notice of Allowance for U.S. Patent for Ovarian Cancer Treatment
microRNA therapeutic approach complements company's ovarian cancer predictive biomarker work.
Saturday, July 12, 2014
Rosetta Genomics, Moffitt Cancer Center Enter mRNA-Based Cancer Diagnostic Agreement
Partnership to advance the development and commercialization of Rosetta's thyroid neoplasia assay.
Tuesday, June 10, 2014
Rosetta Genomics, Clait Health Services Enter mRNA Collaboration
Partnership with Clalit Health Services' Rabin Medical Center will develop a non-invasive, microRNA-based, assay for the diagnosis of CAD following kidney transplantation.
Tuesday, March 25, 2014
Rosetta Genomics to Receive U.S. Patent for Oncology Therapeutic
Company receives a Notice of Allowance from the USPTO for a patent claiming Mp53-negative cancer patients.
Thursday, February 27, 2014
Rosetta Genomics Appoints Kevin Watson
Recognized expert in healthcare policy and reimbursement to lead payer efforts for Company's line of microRNA diagnostics.
Thursday, February 20, 2014
Rosetta Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer
Expands the Company's patent portfolio in oncology therapeutics.
Monday, November 11, 2013
Scientific News
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
The Genetics of Blood Pressure
Researchers have identifed areas of the genome associated with blood-pressure including 17 previously unknown loci.
Mosquito Genetics Determine Tastes
Study reveals mosuito's preference for human versus animal biting is determined by genetics.
Quadruple Helix DNA Aids Cancer Therapies
Researchers have identified the role that a four-stranded version of DNA may play in the role of cancer progression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!